Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 3
2014 3
2015 6
2016 12
2017 8
2018 8
2019 11
2020 7
2021 12
2022 16
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Gastric neuroendocrine tumor G1"
Page 1
Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Xu Z, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2124750. doi: 10.1001/jamanetworkopen.2021.24750. JAMA Netw Open. 2021. PMID: 34554237 Free PMC article.
IMPORTANCE: Although the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been thought to have increased during the past decades, updated epidemiologic and survival data are lacking. ...On multivariable analyses, age, sex, mar …
IMPORTANCE: Although the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been thought …
Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S, Vanoli A. La Rosa S, et al. J Clin Pathol. 2014 Nov;67(11):938-48. doi: 10.1136/jclinpath-2014-202515. Epub 2014 Jul 22. J Clin Pathol. 2014. PMID: 25053544 Review.
Gastric neuroendocrine neoplasms (NENs) are a heterogeneous group of tumours showing different clinicopathological features and behaviour, implying a wide spectrum of therapeutic options. They are currently classified using the 2010 WHO classification of digestive …
Gastric neuroendocrine neoplasms (NENs) are a heterogeneous group of tumours showing different clinicopathological features an …
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G, Circelli L, Savarese G, Di Somma C, Savastano S, Colao A, Faggiano A. Altieri B, et al. Endocrine. 2022 Feb;75(2):623-634. doi: 10.1007/s12020-021-02869-w. Epub 2021 Sep 17. Endocrine. 2022. PMID: 34533768
PURPOSE: Data regarding vitamin D status in patients affected by gastroenteropancreatic (GEP) neuroendocrine tumor (NET) are limited and often showing contrasting results. ...No correlation with somatostatin analogs treatment was found. 25(OH)D levels were significa …
PURPOSE: Data regarding vitamin D status in patients affected by gastroenteropancreatic (GEP) neuroendocrine tumor (NET) are l …
Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel M, Pascher A, Pape UF. Felder S, et al. Endocr Relat Cancer. 2019 Sep;26(9):751-763. doi: 10.1530/ERC-18-0582. Endocr Relat Cancer. 2019. PMID: 31272081 Free PMC article.
Although gastric neuroendocrine neoplasias (gNEN) are an orphan disease, their incidence is rising. ...Particularly careful analysis of the clinical course of gNEN-1 (ECLomas, gastric carcinoids) confirmed their mostly benign, but recurrent and extremely slow …
Although gastric neuroendocrine neoplasias (gNEN) are an orphan disease, their incidence is rising. ...Particularly careful an …
Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.
Boeriu A, Dobru D, Fofiu C, Brusnic O, Onişor D, Mocan S. Boeriu A, et al. Medicine (Baltimore). 2022 Jan 14;101(2):e28550. doi: 10.1097/MD.0000000000028550. Medicine (Baltimore). 2022. PMID: 35029217 Free PMC article. Review.
RATIONALE: Gastric neuroendocrine neoplasms (g-NENs) represent a distinctive group of gastric tumors, stratified into different prognostic categories according to different histological characteristics, put forth in the 2018 World Health Organization c …
RATIONALE: Gastric neuroendocrine neoplasms (g-NENs) represent a distinctive group of gastric tumors, stratified …
Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S. Cavalcoli F, et al. Medicina (Kaunas). 2023 Oct 1;59(10):1757. doi: 10.3390/medicina59101757. Medicina (Kaunas). 2023. PMID: 37893475 Free PMC article. Review.
Background and Objectives: Gastric neuroendocrine neoplasms (gNENs) represent rare but increasingly recognized tumors. They are distinguished into three main clinical types (type-1, type-2, and type-3) according to gastrin level and at histological evaluation …
Background and Objectives: Gastric neuroendocrine neoplasms (gNENs) represent rare but increasingly recognized tumors. …
PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?
Kong G, Hicks RJ. Kong G, et al. Curr Opin Pharmacol. 2022 Dec;67:102293. doi: 10.1016/j.coph.2022.102293. Epub 2022 Oct 1. Curr Opin Pharmacol. 2022. PMID: 36195008 Review.
Peptide receptor radionuclide therapy (PRRT) is a widely accepted treatment for progressive grade 1 and 2 (G1-2) gastroenteropancreatic neuroendocrine tumors (NET). There is increasing evidence that PRRT is effective for selected patients with well-differenti …
Peptide receptor radionuclide therapy (PRRT) is a widely accepted treatment for progressive grade 1 and 2 (G1-2) gastroenteropancreat …
The meaning of R1 resection after endoscopic removal of gastric, duodenal and rectal neuroendocrine tumors.
Esposito G, Dell'Unto E, Ligato I, Marasco M, Panzuto F. Esposito G, et al. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(8):785-793. doi: 10.1080/17474124.2023.2242261. Epub 2023 Jul 31. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37497604 Review.
INTRODUCTION: Well-differentiated gastric, duodenal, and rectal neuroendocrine neoplasms (NETs) are rare diseases usually managed by endoscopic treatment. ...EXPERT OPINION: An incomplete R1 finding may have no significant impact on a patient's clinical outcome, par …
INTRODUCTION: Well-differentiated gastric, duodenal, and rectal neuroendocrine neoplasms (NETs) are rare diseases usually mana …
Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2.
Chen S, Sun L, Chen H, Li J, Lu C, Yang Y, Sun Y. Chen S, et al. Histopathology. 2023 Nov;83(5):700-711. doi: 10.1111/his.15002. Epub 2023 Jul 5. Histopathology. 2023. PMID: 37403531
AIMS: To characterise the clinicopathological and genetic characteristics of gastric neuroendocrine tumour G3 (gNET G3) and to compare them with those of gastric neuroendocrine carcinoma (gNEC) and gNET G2. METHODS AND RESULTS: A total of 115 …
AIMS: To characterise the clinicopathological and genetic characteristics of gastric neuroendocrine tumour G3 (gNET G3) …
Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, Kim KM, Kim JJ. Min BH, et al. Br J Surg. 2018 Oct;105(11):1480-1486. doi: 10.1002/bjs.10901. Epub 2018 Jun 12. Br J Surg. 2018. PMID: 29893418
BACKGROUND: With the widespread use of endoscopy, small and low-grade type 3 gastric neuroendocrine tumours (NETs) are increasingly being detected. ...Wedge or endoscopic resection may be a valid option for patients with type 3 gastric G1 NET no larger …
BACKGROUND: With the widespread use of endoscopy, small and low-grade type 3 gastric neuroendocrine tumours (NETs) are increas …
88 results